This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Laborie Medical Technologies to Acquire Cogentix Medical
by Zacks Equity Research
Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical (CGNT) for a net worth of $239 million.
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
by Zacks Equity Research
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
Cogentix Medical (CGNT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.
AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
by Zacks Equity Research
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.
ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern
by Zacks Equity Research
ABIOMED (ABMD) is focusing heavily in its proprietary Impella Platform to enhance customer base.
Allscripts Rides High on Product Launches Amid Rising Costs
by Zacks Equity Research
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.
BD (BDX) Inks New Deal to Strengthen Foothold in STI Space
by Zacks Equity Research
BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.
Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
by Zacks Equity Research
Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.
Varian Conducts Clinical Workshop, Strengthens Algeria Hold
by Zacks Equity Research
Varian (VAR) has 30 systems operating in Algeria at the moment. The latest development signifies the company's long-term goal of serving six million cancer patients every year.
AngioDynamics' BioFlo Platform Strong, Debt Levels High
by Zacks Equity Research
AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.
Allscripts' Latest Initiative Eradicates Price Ambiguity
by Zacks Equity Research
Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.
DaVita's (DVA) Green Initiatives Win a Coveted Golden Reward
by Zacks Equity Research
DaVita's (DVA) environment-friendly operations are likely to enhance the company's long-term sustainable growth. Also, strong patient services drive DaVita's success story.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Baxter (BAX) reaches a 52-week high on the back of an impressive product line. Buoyed by last quarter's stellar growth in earnings and sales, the company also raises long-term outlook.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
The Cooper Companies (COO) Beats Earnings Estimates in Q3
by Zacks Equity Research
The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.
NxStage System One Gets FDA Nod for Solo Home Hemodialysis
by Zacks Equity Research
The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
by Zacks Equity Research
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates
by Zacks Equity Research
Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.
5 Bargain Breakout Stocks Offering Stunning Returns
by Swarup Gupta
The key to this kind of stock selection is to identify players that are trading within a narrow band.